CN108721257B - Application of patchouli alcohol in preparation of endothelium-independent vasodilator - Google Patents
Application of patchouli alcohol in preparation of endothelium-independent vasodilator Download PDFInfo
- Publication number
- CN108721257B CN108721257B CN201810379433.0A CN201810379433A CN108721257B CN 108721257 B CN108721257 B CN 108721257B CN 201810379433 A CN201810379433 A CN 201810379433A CN 108721257 B CN108721257 B CN 108721257B
- Authority
- CN
- China
- Prior art keywords
- patchouli alcohol
- endothelium
- preparation
- independent
- patchouli
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Cardiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Heart & Thoracic Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention discloses an application of patchouli alcohol in preparing an endothelium-independent vasodilator. The invention also discloses a medicament for treating cardiovascular and cerebrovascular diseases caused by endothelial injury, which is a preparation prepared by taking patchouli alcohol as an active ingredient and adding pharmaceutically acceptable auxiliary materials or auxiliary ingredients. The patchouli alcohol has the vasodilatation effect independent of endothelium, and has great clinical significance for treating cardiovascular and cerebrovascular diseases.
Description
Technical Field
The invention relates to a new application of patchouli alcohol, in particular to an application in preparing endothelium-independent vasodilators, belonging to the field of medicaments.
Background
Vasodilators are mainly used in the treatment of hypertension, congestive heart failure, myocardial ischemia, cerebral ischemia and peripheral vasospastic disorders. Vasodilators can be divided into two main classes depending on the vasodilating route: endothelium-dependent vasodilators, which are dependent on functionally and structurally intact bloodSynthesis and secretion of NO and PGI by endothelial cells2Vasodilation due to increase in vasodilating factors such as EDHF and/or decrease in vasoconstricting factors such as ET-1; endothelial independent vasodilators, which refers to the release of NO directly through the vascular smooth muscle itself independent of vascular endothelial cells, K+Activation of channels, and/or Ca2 +Channel blockage, etc. causing vasodilation.
Research proves that the occurrence and development of cardiovascular and cerebrovascular diseases are closely related to vascular endothelial loss and endothelial function damage. However, currently, the commonly used drugs for endothelium-dependent vasodilation in clinic, such as HMG-COA reductase inhibitors, angiotensin converting enzyme inhibitors, angiotensin II receptor blockers, endothelin receptor antagonists, beta receptor blockers, antioxidants, l-arginine, etc., have poor effects on patients with hypertension and cardiovascular and cerebrovascular diseases with vascular endothelial injury. Therefore, the search for endothelium-independent vasodilators is very important, and especially the vasodilators extracted from natural drugs have great clinical significance.
Patchouli alcohol, also known as patchouli alcohol, is a tricyclic sesquiterpene compound mainly existing in natural plant patchouli, and its molecular formula is C15H26O, molecular weight 222.37, is colorless crystal, and has light fragrance of herba Agastaches. Melting point 55-56 deg.C, boiling point 280 deg.C, relative density 1.0284, and optical rotation-97.4 deg. (c 24, chloroform). Is insoluble in water, and soluble in petroleum ether, ethanol and other common organic solvents.
Patchouli alcohol
Modern pharmacological research shows that patchouli alcohol has the functions of regulating immunity, resisting inflammation, resisting oxidation, resisting tumor, resisting pathogenic microorganism (including bacteria, virus and fungi), tranquilizing, killing parasite and arresting vomiting. There is no report of patchouli alcohol in relation to endothelium independent vasodilation.
Disclosure of Invention
The invention aims to provide application of the endothelium independent vasodilator.
The invention provides an application of patchouli alcohol in preparing an endothelium-independent vasodilator.
Wherein the vasodilator is a medicament for treating cardiovascular and cerebrovascular diseases.
Wherein the vasodilator is a medicament for treating cardiovascular and cerebrovascular diseases accompanied with endothelial injury.
Wherein the cardiovascular and cerebrovascular diseases are hypertension, coronary heart disease, congestive heart failure, cerebral apoplexy and/or peripheral vasospastic diseases.
The invention also provides a medicament for treating cardiovascular and cerebrovascular diseases caused by endothelial injury, which is a preparation prepared from patchouli alcohol serving as an active ingredient and pharmaceutically acceptable auxiliary materials or auxiliary ingredients.
Wherein the preparation is a liquid preparation, a gas preparation, a solid preparation and a semi-solid preparation.
The patchouli alcohol has the effect of endothelium-independent vasodilatation, has high sensitivity, has excellent curative effect on cardiovascular and cerebrovascular diseases accompanied with endothelial injury, and has important clinical significance for treating the cardiovascular and cerebrovascular diseases.
Obviously, many modifications, substitutions, and variations are possible in light of the above teachings of the invention, without departing from the basic technical spirit of the invention, as defined by the following claims.
The present invention will be described in further detail with reference to the following examples. This should not be understood as limiting the scope of the above-described subject matter of the present invention to the following examples. All the technologies realized based on the above contents of the present invention belong to the scope of the present invention.
Detailed Description
Example 1: patchouli alcohol concentration-dependent vasodilation potassium chloride preshrysed endothelialized vascular ring effect
1 materials and instruments
1.1 medicine and preparation
The herba Agastaches medicinal material was collected from herba Agastaches planting base in Yangchun county of Guangdong province in 11 months of 2012, and identified as whole herb of herba Agastaches (Pogostemon cablin (Blanco) Benth.) of Pogostemon of Labiatae by Dr-Jordan Chinese medicine identification and textbook-Fei doctor of Chengdu Chinese medicine university.
Taking 40Kg of overground part of dried cablin potchouli herb, extracting by adopting a large-scale improved steam distillation device, and drying and removing water by anhydrous sodium sulfate to finally obtain 215g of cablin potchouli herb volatile oil. Separating volatile oil by silica gel column chromatography (100-200 mesh, 5Kg, 20 × 150cm), gradient eluting with petroleum ether-acetone (100: 0-0: 100) as mobile phase, detecting eluate by thin layer chromatography, mixing fractions with similar composition, and recovering solvent to obtain 31 eluate fractions (F1-F31). F12 (petroleum ether-acetone 50:1 elution) partially precipitated white solid, was fragrant, partially placed in n-hexane, precipitated white crystals, and was purified by repeated recrystallization to give compound (30.8 g).
Through structural identification, the compound is
Patchouli alcohol
The purity of the product is over 98% by content measurement.
1.2 animals
The adult Jiankang SD male rat of SPF grade weighs 180-220g, is provided by animal research institute of Sichuan province medical science institute, and has a license number of: SCXK 2013-15. The breeding temperature is 21-27 ℃, the humidity is 50 +/-5%, and the illumination and ventilation environment is naturally adjusted day and night. The experimental procedures were strictly in accordance with the animal management rules.
1.3 instruments and reagents
M870B5/10 type four-channel isolated tissue perfusion system, ML870 type Powerlab biosignal collection system, MLT0201 type tension transducer, Labchart Pro professional version software were purchased from Ed instruments International trade (Shanghai) Inc. Sodium chloride (Chengduo chemical reagent factory, lot number: 2015120701); potassium chloride (Chengduo chemical reagent factory, batch number: 2015042301); potassium dihydrogen phosphate (Chengduo Kelong chemical reagent factory, batch number: 2016042801); magnesium sulfate (WUDUNKELONG CHEMICAL REAGENT WORK, lot number 2015090101); sodium bicarbonate (Doxolone chemical reagent plant, batch number: 2015122201); calcium chloride (Chengduo chemical reagent factory, batch number: 2015080101); glucose (Tandon chemical reagent factory, batch number: 2015110701); phenylephrine (Sigma, lot number: 1000957684); acetylcholine (Bomei, batch: A0041).
2 test method
The thoracic aortic annulus of the rat was prepared according to the methods of the prior art. Rats were sacrificed by cervical dislocation, the thoracic aorta rapidly removed and placed in oxygen-saturated 4 ℃ K-H solution (mM): sodium chloride (118.4), potassium chloride (4.7), calcium chloride (2.5), potassium dihydrogen phosphate (1.2), magnesium sulfate (1.2), sodium bicarbonate (25.0), glucose (10.1), removing peripheral connective tissue, and cutting into 3-5mm blood vessel ring. Successful removal of the endothelium can be confirmed by passing a forceps through the lumen of the vascular ring and gently rolling over moistened sterile gauze by the following procedure: phenylephrine (1 μ M) contracted the vascular ring, after the contractile tension reached plateau, acetylcholine (10 μ M) was added to the trough with a diastolic amplitude of less than 10%. The vascular ring with the inner skin removed is horizontally suspended in the bath tube by two stainless steel pedal type hooks, one end of the vascular ring is fixed in the bath tube, the other end of the vascular ring is connected with a tension transducer, and a PowerLab biological signal acquisition system is used for acquiring and recording the change of tension. After equilibration with a 60min preload of 1g, 60mM potassium chloride serially stimulated the vascular ring 3 times to establish a reproducible contraction curve.
The curve of the percentage relaxation of the cumulative response concentration of patchouli alcohol solution (dissolved in DMSO) was obtained with 100% of the maximal contractile tension induced by 60mM potassium chloride on the de-endothelialized thoracic aortic annulus. The relaxation of patchouli alcohol is concentration dependent endothelium independent.
3, test results:
(1) 1 μ M patchouli alcohol produced a diastolic response with an amplitude of 3.30% based on 100% maximum contractile tension of the potassium chloride pre-contracted, de-endothelialized thoracic aortic annulus.
(2) The amplitude of the diastolic response by 3 μ M patchouli alcohol was 20.43% based on 100% maximum contractile tension of the potassium chloride pre-contracted, de-endothelialized thoracic aortic ring.
(3) The amplitude of the diastolic response produced by 10 μ M patchouli alcohol was 61.67% based on 100% maximum contractile tension of the potassium chloride pre-contracted, de-endothelialized thoracic aortic ring.
(4) The amplitude of the diastolic response produced by 30 μ M patchouli alcohol was 87.27% based on 100% maximum contractile tension of the potassium chloride pre-contracted, de-endothelialized thoracic aortic annulus.
(5) 100 μ M patchouli alcohol produced a diastolic response of 96.76% based on 100% maximum contractile tension of the potassium chloride pre-contracted, de-endothelialized thoracic aortic annulus.
The results of the experiments show the sensitivity of the diastolic response to patchouli alcohol production (pD) based on 100% of the maximal contractile tension of the potassium chloride preshrysed, de-endothelialized thoracic aortic annulus2) Is 5.14. The experimental result shows that the patchouli alcohol has the vasodilation effect without endothelial vessels and has high sensitivity.
Example 2: patchouli alcohol concentration dependent vasodilation phenylephrine preshrysed endotheliocyte ring effect
1 materials and instruments
1.1 medicine and preparation
The herba Agastaches medicinal material was collected from herba Agastaches planting base in Yangchun county of Guangdong province in 11 months of 2012, and identified as whole herb of herba Agastaches (Pogostemon cablin (Blanco) Benth.) of Pogostemon of Labiatae by Dr-Jordan Chinese medicine identification and textbook-Fei doctor of Chengdu Chinese medicine university.
Taking 40Kg of overground part of dried cablin potchouli herb, extracting by adopting a large-scale improved steam distillation device, and drying and removing water by anhydrous sodium sulfate to finally obtain 215g of cablin potchouli herb volatile oil. Separating volatile oil by silica gel column chromatography (100-200 mesh, 5Kg, 20 × 150cm), gradient eluting with petroleum ether-acetone (100: 0-0: 100) as mobile phase, detecting eluate by thin layer chromatography, mixing fractions with similar composition, and recovering solvent to obtain 31 eluate fractions (F1-F31). F12 (petroleum ether-acetone 50:1 elution) partially precipitated white solid, was fragrant, partially placed in n-hexane, precipitated white crystals, and was purified by repeated recrystallization to give compound (30.8 g).
Through structural identification, the compound is
Patchouli alcohol
The purity of the product is over 98% by content measurement.
1.2 animals
The adult Jiankang SD male rat of SPF grade weighs 180-220g, is provided by animal research institute of Sichuan province medical science institute, and has a license number of: SCXK 2013-15. The breeding temperature is 21-27 ℃, the humidity is 50 +/-5%, and the illumination and ventilation environment is naturally adjusted day and night. The experimental procedures were strictly in accordance with the animal management rules.
1.3 instruments and reagents
M870B5/10 type four-channel isolated tissue perfusion system, ML870 type Powerlab biosignal collection system, MLT0201 type tension transducer, Labchart Pro professional version software were purchased from Ed instruments International trade (Shanghai) Inc. Sodium chloride (Chengduo chemical reagent factory, lot number: 2015120701); potassium chloride (Chengduo chemical reagent factory, batch number: 2015042301); potassium dihydrogen phosphate (Chengduo Kelong chemical reagent factory, batch number: 2016042801); magnesium sulfate (WUDUNKELONG CHEMICAL REAGENT WORK, lot number 2015090101); sodium bicarbonate (Doxolone chemical reagent plant, batch number: 2015122201); calcium chloride (Chengduo chemical reagent factory, batch number: 2015080101); glucose (Tandon chemical reagent factory, batch number: 2015110701); phenylephrine (Sigma, lot number: 1000957684); acetylcholine (Bomei, batch: A0041).
2 test method
The thoracic aortic annulus of the rat was prepared according to the methods of the prior art. Rats were sacrificed by cervical dislocation, the thoracic aorta rapidly removed and placed in oxygen-saturated 4 ℃ K-H solution (mM): sodium chloride (118.4), potassium chloride (4.7), calcium chloride (2.5), potassium dihydrogen phosphate (1.2), magnesium sulfate (1.2), sodium bicarbonate (25.0), glucose (10.1), removing peripheral connective tissue, and cutting into 3-5mm blood vessel ring. Successful removal of the endothelium can be confirmed by passing a forceps through the lumen of the vascular ring and gently rolling over moistened sterile gauze by the following procedure: phenylephrine (1 μ M) contracted the vascular ring, after the contractile tension reached plateau, acetylcholine (10 μ M) was added to the trough with a diastolic amplitude of less than 10%. The vascular ring with the inner skin removed is horizontally suspended in the bath tube by two stainless steel pedal type hooks, one end of the vascular ring is fixed in the bath tube, the other end of the vascular ring is connected with a tension transducer, and a PowerLab biological signal acquisition system is used for acquiring and recording the change of tension. After equilibration with a 60min preload of 1g, 60mM potassium chloride serially stimulated the vascular ring 3 times to establish a reproducible contraction curve.
The curve of the percentage relaxation of the cumulative response concentration of patchouli alcohol solution (dissolved in DMSO) was obtained with 100% of the maximal contractile tension of the de-endothelialized thoracic aortic annulus induced by 1. mu.M phenylephrine. The relaxation of patchouli alcohol is concentration dependent endothelium independent.
3, test results:
(1) 1 μ M patchouli alcohol produced a diastolic response of 2.08% based on 100% maximum contractile tension of the phenylephrine pre-contracted denervated thoracic aortic ring.
(2) The amplitude of the diastolic response by 3 μ M patchouli alcohol was 7.17% based on 100% maximum contractile tension of the phenylephrine pre-contracted denervated thoracic aortic ring.
(3) The amplitude of the diastolic response by 10 μ M patchouli alcohol was 14.01% based on 100% maximum contractile tension of the phenylephrine pre-contracted denervated thoracic aortic ring.
(4) The amplitude of the diastolic response by 30 μ M patchouli alcohol was 20.48% based on 100% maximum contractile tension of the phenylephrine pre-contracted denervated thoracic aortic ring.
(5) 100 μ M patchouli alcohol produced a diastolic response of 60.46% based on 100% maximum contractile tension of the phenylephrine pre-contracted denervated thoracic aortic annulus.
(6) The amplitude of the diastolic response by 300 μ M patchouli alcohol was 95.25% based on 100% maximum contractile tension of the phenylephrine pre-contracted denervated thoracic aortic ring.
The results of the experiments show the sensitivity of the diastolic response to patchouli alcohol production (pD) based on 100% of the maximal contractile tension of the potassium chloride preshrysed, de-endothelialized thoracic aortic annulus2) Was 4.12. The experimental result shows that the patchouli alcohol has the vasodilation effect without endothelial vessels and has high sensitivity.
The occurrence and development of cardiovascular and cerebrovascular diseases (including hypertension) are closely related to vascular endothelial loss and endothelial function damage, and the hypertension is also the first cause of the occurrence of the cardiovascular and cerebrovascular diseases. The beneficial effects of the invention are further demonstrated by means of experimental hypertension examples as follows:
experimental example 1 treatment of hypertension with patchouli alcohol
1 materials and instruments
1.1 medicine and preparation
The herba Agastaches medicinal material was collected from herba Agastaches planting base in Yangchun county of Guangdong province in 11 months of 2012, and identified as whole herb of herba Agastaches (Pogostemon cablin (Blanco) Benth.) of Pogostemon of Labiatae by Dr-Jordan Chinese medicine identification and textbook-Fei doctor of Chengdu Chinese medicine university.
Taking 40Kg of overground part of dried cablin potchouli herb, extracting by adopting a large-scale improved steam distillation device, and drying and removing water by anhydrous sodium sulfate to finally obtain 215g of cablin potchouli herb volatile oil. Separating volatile oil by silica gel column chromatography (100-200 mesh, 5Kg, 20 × 150cm), gradient eluting with petroleum ether-acetone (100: 0-0: 100) as mobile phase, detecting eluate by thin layer chromatography, mixing fractions with similar composition, and recovering solvent to obtain 31 eluate fractions (F1-F31). F12 (petroleum ether-acetone 50:1 elution) partially precipitated white solid, was fragrant, partially placed in n-hexane, precipitated white crystals, and was purified by repeated recrystallization to give compound (30.8 g).
Through structural identification, the compound is
Patchouli alcohol
The purity of the product is over 98% by content measurement. The patchouli alcohol is prepared into 8, 4 and 2 mg/mL by using special virgin olive oil (Chengdu Frey olive development Co., Ltd., product standard code: GB23347-2009) respectively-1And storing in a refrigerator at 4 ℃ for later use.
The captopril tablet (Kantopri Kaishu pharmaceutical Co., Ltd., batch No. 161115, Shantou dynasty) was prepared into 0.25 mg/mL with 0.9% physiological saline-1And storing in a refrigerator at 4 ℃ for later use.
1.2 animals
8-week-old SPF-grade Spontaneous Hypertension Rats (SHR) 60, Wei-Kaybi rats (Wistar-Kyoto rat, WKY)10, body weight 180-: SCXK (Jing) 2012 and 0001. Can be freely eaten and drunk, is naturally illuminated, has room temperature of 24 +/-2 ℃, relative humidity of 60 +/-5 percent, is naturally adjusted in a ventilation environment, and is periodically changed with water and a feces tray. The feed is purchased from Sichuan Dao laboratory animals, Inc., and the production license number is as follows: SCXK 2013-15. The experimental procedures were strictly in accordance with the animal management rules.
1.3 instruments
BP-6A automatic noninvasive blood pressure measuring instrument (Chengdutai alliance, Inc.).
2 test method
SHR 60 individuals with age of 8 weeks, half male and female, after adaptive feeding for 1 week, randomly divided into SHR group (equal dosage of normal saline), solvent group (equal dosage of extra virgin olive oil), and patchouli alcohol high (80 mg. Kg)-1) Middle (40 mg. Kg)-1) Low dose (20 mg. Kg)-1) Group and positive group (captopril, 2.5 mg. Kg)-1) Each group comprises 10 male and female halves. In addition, 10 WKY rats of the same week age were used as normal control groups (equal dose of physiological saline), and male and female rats were divided into halves. The administration volume is 10mL Kg-1Once daily gavage for 8 weeks. Monitoring rats 1 week before and weekly after dosingSystolic tail blood pressure (SBP).
3 results of the experiment
The results are shown in Table 1.
Rats 1 male dead rat per SHR group and positive (captopril) group during adaptive blood pressure measurement.
Compared with the WKY group, the SBP of the SHR group rats is remarkably increased (p <0.01), and the blood pressure is increased in fluctuation with the increase of the week age, which is probably related to the change of the female SHR blood pressure fluctuation. Compared with the SHR group, the SBP of the patchouli alcohol high-dose group is obviously reduced at 6, 7 and 8 weeks after the administration (p < 0.05); the dose group SBP in patchouli alcohol significantly decreased at weeks 7 and 8 after dosing (p < 0.01); the SBP of the patchouli alcohol low dose group was significantly reduced at week 8 after dosing (p < 0.05); the SBP of the captopril group is reduced to different degrees in each week after administration, and particularly has obvious effects (p <0.05 or p <0.01) at 3, 5, 6 and 8 weeks after administration; SBP was not significantly affected by the week after vehicle administration (p > 0.05).
Experimental results prove that the SBP of the rats in the low, medium and high dose patchouli alcohol test groups is obviously reduced after administration for a period of time, and the SBP has obvious difference compared with a model control group. In addition, the onset time of the blood pressure reducing effect of patchouli alcohol is obviously dependent on the dosage thereof, but the blood pressure reducing amplitude is not obviously dependent on the dosage thereof. The patchouli alcohol can effectively reduce blood pressure and has mild effect.
In conclusion, the experiment proves that the patchouli alcohol has a definite effect on endothelium-independent vasodilation, is high in sensitivity and mild in effect, provides a new choice for clinically screening and/or preparing the medicine for treating hypertension, and has great clinical significance for treating cardiovascular and cerebrovascular diseases.
Claims (1)
1. Use of patchouli alcohol as the sole active ingredient for the preparation of an endothelial independent vasodilator, which is a blood pressure lowering drug.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2017102845400 | 2017-04-25 | ||
| CN201710284540 | 2017-04-25 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN108721257A CN108721257A (en) | 2018-11-02 |
| CN108721257B true CN108721257B (en) | 2021-09-10 |
Family
ID=63939219
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201810379433.0A Expired - Fee Related CN108721257B (en) | 2017-04-25 | 2018-04-25 | Application of patchouli alcohol in preparation of endothelium-independent vasodilator |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN108721257B (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110201177B (en) * | 2019-06-18 | 2020-05-19 | 中国人民解放军总医院第八医学中心 | Pharmaceutical composition for preventing and treating coronary heart disease and application thereof |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103127038A (en) * | 2012-03-16 | 2013-06-05 | 成都华神集团股份有限公司 | Novel application of patchouli alcohol |
| WO2013129769A1 (en) * | 2012-02-29 | 2013-09-06 | 목포대학교 산학협력단 | Composition for treating or preventing hypertension |
-
2018
- 2018-04-25 CN CN201810379433.0A patent/CN108721257B/en not_active Expired - Fee Related
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013129769A1 (en) * | 2012-02-29 | 2013-09-06 | 목포대학교 산학협력단 | Composition for treating or preventing hypertension |
| CN103127038A (en) * | 2012-03-16 | 2013-06-05 | 成都华神集团股份有限公司 | Novel application of patchouli alcohol |
Non-Patent Citations (1)
| Title |
|---|
| Patchouli alcohol protects against ischemia/reperfusion-induced braininjury via inhibiting neuroinflammation in normal and obese mice;Li-li Wei等;《Brain Research》;20171230(第1682期);61-70 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN108721257A (en) | 2018-11-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN100464756C (en) | Application of fucoidan in the preparation of medicine and health-care products for preventing and treating neurodegenerative diseases | |
| JP2017537092A (en) | Formulation containing chlorogenic acid crystal form and use thereof | |
| AU2021469614A1 (en) | Use of composition comprising astilbin and/or isomer thereof in preparation of drug for treating psoriasis | |
| KR20150116659A (en) | Composition for Improving Skin Conditions Comprising Andrographis paniculata Extract or andrographolide or salts thereof | |
| CN108721257B (en) | Application of patchouli alcohol in preparation of endothelium-independent vasodilator | |
| CN101590065A (en) | Siberia Radix Polygalae sugar A1, Siberia Radix Polygalae sugar A5 and the tenuifoliside A application in preparation treatment depression product | |
| CN103169743A (en) | Mango leaf extractive as well as preparation method and application thereof | |
| CN103360456B (en) | Triterpene compound and Synthesis and applications | |
| CN109453162A (en) | Application, pharmaceutical composition and application of the amentoflavone in preparation protection and/or reparation nerve cell drug | |
| CN110507647B (en) | Application of andrographolide sodium bisulfite in preparing medicine for treating hyperlipemia | |
| CN100467025C (en) | Use of asiaticoside in preparation of medicines for diseases of cardio-cerebral blood vessels | |
| US8455014B2 (en) | Composition comprising Trachelospermi caulis and Pyrola japonica extracts for the treatment and prevention of inflammatory diseases | |
| WO2023137962A1 (en) | Oxidized isoaporphine alkaloid derivative, and preparation method therefor and anti-depressant use thereof | |
| CN112274542B (en) | Application of semiliquidambar cathayensis aqueous extract in preparation of anti-depression drugs | |
| CN111423484B (en) | Beta sitosterol derivative and preparation method and application thereof | |
| JP5086805B2 (en) | "Preparation of purified anti-cancer ginseng extract and its cancer fusion preparation" | |
| CN103288914B (en) | Preparation method of traditional Chinese medicine manyflower tickclove herb extract and application in anti-senile dementia medicaments | |
| CN102389425B (en) | Application of nicotinic acid derivates in preparation of medicaments for promoting follicular development and maintaining ovarian functions | |
| CN110063988A (en) | A kind of pharmaceutical composition and preparation method thereof for treating neuroblastoma | |
| CN101048154A (en) | Antiprotozoal agent | |
| WO2001058888A1 (en) | A sesquiterpenoic compound and pharmaceutical formulations comprising the same | |
| CN113694055B (en) | Application of agalloch eaglewood tetrol in preparing medicine for treating vascular dementia | |
| CN102838645B (en) | Polyphenol hydroxy flavone compound with pharmaceutical function and preparation method thereof | |
| CN114409544B (en) | Phenylpropanoid with vasodilation activity, and extraction method and application thereof | |
| JP6469518B2 (en) | Angiogenesis promoter |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20210910 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |